Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis

Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephal...

Descripción completa

Detalles Bibliográficos
Autores principales: Monson, Nancy L., Cravens, Petra, Hussain, Rehana, Harp, Christopher T., Cummings, Matthew, de Pilar Martin, Maria, Ben, Li-Hong, Do, Julie, Lyons, Jeri-Anne, Lovette-Racke, Amy, Cross, Anne H., Racke, Michael K., Stüve, Olaf, Shlomchik, Mark, Eagar, Todd N.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040191/
https://www.ncbi.nlm.nih.gov/pubmed/21359213
http://dx.doi.org/10.1371/journal.pone.0017103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040191/
https://www.ncbi.nlm.nih.gov/pubmed/21359213
http://dx.doi.org/10.1371/journal.pone.0017103

Ejemplares similares